AnaptysBio Inc
NASDAQ:ANAB

Watchlist Manager
AnaptysBio Inc Logo
AnaptysBio Inc
NASDAQ:ANAB
Watchlist
Price: 22.27 USD 5.2% Market Closed
Market Cap: 677.7m USD
Have any thoughts about
AnaptysBio Inc?
Write Note

AnaptysBio Inc
EPS (Diluted)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

AnaptysBio Inc
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
AnaptysBio Inc
NASDAQ:ANAB
EPS (Diluted)
-$5
CAGR 3-Years
N/A
CAGR 5-Years
-10%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
EPS (Diluted)
$2
CAGR 3-Years
-12%
CAGR 5-Years
6%
CAGR 10-Years
2%
Gilead Sciences Inc
NASDAQ:GILD
EPS (Diluted)
$0
CAGR 3-Years
-75%
CAGR 5-Years
-47%
CAGR 10-Years
-34%
Amgen Inc
NASDAQ:AMGN
EPS (Diluted)
$7
CAGR 3-Years
-7%
CAGR 5-Years
-10%
CAGR 10-Years
2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
EPS (Diluted)
-$1
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
2%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
EPS (Diluted)
$40
CAGR 3-Years
-13%
CAGR 5-Years
16%
CAGR 10-Years
30%
No Stocks Found

AnaptysBio Inc
Glance View

Market Cap
677.7m USD
Industry
Biotechnology

AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 102 full-time employees. The company went IPO on 2017-01-26. The firm is focused on the immune control mechanisms applicable to inflammation and immuno-oncology indications. The company develops products using antibody discovery technology platform, which is based upon a natural process of antibody generation, known as somatic hypermutation, and replicates this natural process of antibody generation in vitro. Its advanced antibody programs include: Imsidolimab is an antibody that inhibits the interleukin-36 receptor, for the treatment of inflammatory diseases called generalized pustular psoriasis and hidradenitis suppurativa; Rosnilimab is an anti-PD-1 agonist antibody program, is designed to augment PD-1 signaling through Rosnilimab treatment to suppress T-cell driven human inflammatory diseases; anti-BTLA modulator antibody, known as ANB032, is applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.

ANAB Intrinsic Value
18.18 USD
Overvaluation 18%
Intrinsic Value
Price

See Also

What is AnaptysBio Inc's EPS (Diluted)?
EPS (Diluted)
-5.7 USD

Based on the financial report for Sep 30, 2024, AnaptysBio Inc's EPS (Diluted) amounts to -5.7 USD.

What is AnaptysBio Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-10%

Over the last year, the EPS (Diluted) growth was -3%.

Back to Top